Synthetic Biology Company Raises $20 Million; New Focus on Biofuels
12 October 2006
Amyris Biotechnologies, Inc., a privately-held company applying advances in synthetic biology to produce high-value pharmaceuticals, fine chemicals and biofuels, has raised $20 million in a first round of venture funding.
The Series A financing was led by Khosla Ventures, with additional participation from Kleiner Perkins Caufield & Byers (KPCB), and Texas Pacific Group Ventures (TPGV). The company also announced the appointment of John G. Melo, previously president of US Fuels Operations for BP, as CEO. Also joining the Amyris board at this time are Samir Kaul, general partner, Khosla Ventures; John Doerr, general partner, KPCB; and Geoff Duyk, managing director, TPGV.
Amyris Biotechnologies uses synthetic biology techniques to create new metabolic pathways in industrial microbes to produce novel or rare chemicals. Amyris’ primary project to date has focused on the use of synthetic biology to address supply and cost constraints limiting the use of the anti-malarial drug artemisinin. With the new funding (and CEO), Amyris will work on producing biofuel molecules—ethanol, butanol, or other hydrocarbons.
Greentech could be the largest economic opportunity of the 21st Century. Novel renewable energy sources will be key. John Melo is the perfect CEO to help Amyris innovate and lead in renewable fuels. At BP, he ran a multi-billion fuel operation with early commercial success with ethanol. John’s insights, skills, and relationships are highly complementary to the deep technical talent of the Amyris founders.—John Doerr, KPCB
These new resources will enable the company to expand its capabilities to address major global health and energy challenges, thereby helping to fulfill the promise of synthetic biology. In addition to its ongoing focus on creating a low-cost malaria drug, Amyris will add a new program aimed at renewably producing second-generation, high-performance biofuels with increased cost-effectiveness.—Dr. Jay D. Keasling, Amyris co-founder, head of the company’s Scientific Advisory Board, and UC Berkeley, professor of chemical engineering and bioengineering
“Engineering a mevalonate pathway in Escherichia coli for production of terpenoids”; Vincent J J Martin, Douglas J Pitera, Sydnor T Withers, Jack D Newman & Jay D Keasling; Nature Biotechnology 21, 796 - 802 (2003)
The Second International Conference on Synthetic Biology (Audio archive)
Synthetic Biology (Boston University)
TrackBack URL for this entry:
Listed below are links to weblogs that reference Synthetic Biology Company Raises $20 Million; New Focus on Biofuels: